NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with Irish Pharmacist includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

ADVERTISMENT

ADVERTISMENT

Breakthrough in childhood brain cancer research reveals possible new target for therapies

By Irish Pharmacist - 04th Jun 2025

childhood brain cancer
iStock.com/SeizaVisuals

An international group of scientists has identified a key molecular process that drives a deadly form of childhood brain cancer, potentially offering a much-needed new therapeutic target.

Published in leading international journal Molecular Cell, the new study has revealed how a rare but devastating childhood brain cancer — called Diffuse Midline Glioma (DMG) — hijacks the cell’s gene control machinery to fuel its growth. The findings could point the way to urgently needed new treatments for this currently incurable disease.

DMG is a tumour that develops deep in the brain and primarily affects children and young adults. Nearly all cases carry a key genetic change: A mutation in a protein called histone H3, which helps package DNA inside cells. This mutation disrupts a crucial chemical mark — known as H3K27me3 — that normally acts like a ‘stop sign’ to silence genes.

Scientists had long believed this disruption caused genes to turn on when they shouldn’t. But in a surprising twist, the researchers behind the new study found that parts of this ‘stop sign’ system still remain — and the tumour actually depends on them to survive.

Using cutting-edge genetic screens and molecular tools, the team discovered that a very specific gene-silencing complex — called CBX4/PCGF4-cPRC1 — is essential for the tumour’s growth. Although it makes up less than 5 per cent of the related silencing machinery in the cancer cells, this particular complex plays an outsized role in shutting down genes that would otherwise prevent the tumour from growing.

The study also revealed how a previously unknown region in the CBX4 protein helps it form a special partnership with PCGF4, enabling this harmful gene repression.

“Although this form of PRC1 gene- silencing complex represents less than 5 per cent of PRC1 in these tumours, our research shows it is essential for tumour growth,” said Prof Adrian Bracken, co-lead investigator on the study from Trinity College Dublin’s Smurfit Institute of Genetics. “By specifically targeting this rare form of PRC1, it may be possible to develop more precise treatments that minimise side-effects that can arise with broader-acting therapies.”

Dr Gerard Brien, co-lead investigator from the University of Edinburgh, added: “This discovery sheds light on a key mechanism driving DMG and identifies CBX4 as a promising drug target. Our findings suggest that interfering with CBX4’s interaction with chromatin or its partner protein PCGF4 could disrupt the tumour’s gene-silencing machinery — potentially paving the way for new treatment strategies against this devastating disease.”

ADVERTISMENT

Latest

ADVERTISMENT

ADVERTISMENT

ADVERTISMENT

Latest Issue

Irish Pharmacist June 2025

Irish Pharmacist June 2025

In this issue, earn 2 CPD points by completing our module on Oncology. Also, we feature a special report on medicine shortages in Ireland, including common issues and potential solutions, and Dr Des Corrigan questions whether statistics on Ireland’s drug use problem are misleading…

Read

OTC Spring 2025

This Spring 2025 issue of OTC Update covers a range of pharmacy-related topics. It offers guidance…

Read

ADVERTISMENT

In Focus

ADVERTISMENT

ADVERTISMENT

ADVERTISMENT